Aethlon Medical engages Fabiani & Company to assist in establishment of federal partnerships

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has engaged Fabiani & Company to assist in the establishment of federal partnerships that advance biodefense, cancer, and chronic infectious disease applications of the Aethlon Hemopurifier®. The Aethlon Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. Fabiani & Company is a Washington, D.C.-based government affairs firm founded with the primary goal of providing a select group of clients creative and innovative strategies to effectively represent them and their interests before the United States Federal Government.

"Our colleagues at Fabiani & Company provide us a well respected presence inside the beltway and increase our likelihood of accessing non-dilutive resources to advance our endeavors across multiple disease conditions in the United States," stated Aethlon Chairman and CEO, Jim Joyce.  

"We are pleased and excited to partner with Aethlon Medical," said Fabiani & Company principal, Stephen Conafay. "Aethlon's experienced management team, coupled with their breakthrough Hemopurifier® technology offers to provide a wide variety of cancer and immune suppressed patients a minimally invasive therapeutic strategy at significantly reduced costs when compared to present therapies."